Liu Peng-Lin, Wang Dan-Dan, Pang Cheng-Jian, Zhang Li-Ze
Department of Anorectum, The Affiliated Hospital of Qingdao University, Shandong, China.
Front Oncol. 2022 Nov 18;12:985324. doi: 10.3389/fonc.2022.985324. eCollection 2022.
The NCCN guidelines recommended an assessment of ≥ 12 lymph nodes (LN) as an adequate LN dissection (LND) for rectal cancer (RC). However, the impact of adequate LND on survival in stage I RC patients remained unclear. Thus, we aimed to compare the survival between stage I RC patients with adequate and inadequate LND.
A total of 1,778 stage I RC patients in the SEER database from 2010 to 2017 treated with radical proctectomy were identified. The association between ≥ 12 LND and survival was examined using the multivariate Cox regression and the multivariate competing risk model referenced to < 12 LND.
Stage I RC patients with ≥ 12 LND experienced a significantly lower hazard of cancer-specific death compared with those with < 12 LND in both multivariate Cox regression model (adjusted HR [hazard ratio], 0.44, 95% CI, 0.29-0.66; < 0.001) and the multivariate competing risk model (adjusted subdistribution HR [SHR], 0.45, 95% CI, 0.30-0.69; < 0.001). Further, subgroup analyses performed by pT stage. No positive association between ≥ 12 LND and survival was found in pT1N0 RC patients (adjusted HR: 0.62, 95%CI, 0.32-1.19; = 0.149; adjusted SHR: 0.63, 95%CI, 0.33-1.20; = 0.158), whereas a positive association between ≥ 12 LND and survival was found in pT2N0 RC patients (adjusted HR: 0.35, 95%CI, 0.21-0.58; < 0.001; adjusted SHR: 0.36, 95%CI, 0.21-0.62; < 0.001).
The long-term survival benefit of adequate LND was not found in pT1N0 but in pT2N0 RC patients, which suggested that pT2N0 RC patients should be treated with adequate LND and those with inadequate LND might need additional therapy.
美国国立综合癌症网络(NCCN)指南推荐,对直肠癌(RC)患者进行至少12枚淋巴结(LN)的评估作为充分的淋巴结清扫(LND)。然而,充分的LND对I期RC患者生存的影响仍不明确。因此,我们旨在比较I期RC患者中LND充分与不充分者的生存率。
在监测、流行病学和最终结果(SEER)数据库中,识别出2010年至2017年期间接受根治性直肠切除术的1778例I期RC患者。采用多因素Cox回归和以<12枚LND为参照的多因素竞争风险模型,研究≥12枚LND与生存率之间的关联。
在多因素Cox回归模型(调整后风险比[HR],0.44;95%置信区间[CI],0.29 - 0.66;P<0.001)和多因素竞争风险模型(调整后亚分布风险比[SHR],0.45;95%CI,0.30 - 0.69;P<0.001)中,LND≥12枚的I期RC患者癌症特异性死亡风险均显著低于LND<12枚的患者。此外,按pT分期进行亚组分析。在pT1N0 RC患者中未发现≥12枚LND与生存率之间存在正相关(调整后HR:0.62;95%CI,0.32 - 1.19;P = 0.149;调整后SHR:0.63;95%CI,0.33 - 1.20;P = 0.158),而在pT2N0 RC患者中发现≥12枚LND与生存率之间存在正相关(调整后HR:0.35;95%CI,0.21 - 0.58;P<0.001;调整后SHR:0.36;95%CI,0.21 - 0.62;P<0.001)。
在pT1N0 RC患者中未发现充分的LND具有长期生存获益,但在pT2N0 RC患者中发现了这一获益,这表明pT2N0 RC患者应接受充分的LND治疗,而LND不充分的患者可能需要额外治疗。